A clinical trial of BR111 for injection
Latest Information Update: 20 Feb 2025
At a glance
- Drugs BR 111 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- 20 Feb 2025 New trial record
- 10 Feb 2025 According to a BioRay Pharmaceutical media release, the National Medical Products Administration (NMPA) has accepted the clinical trial application for BR111 for injection for the treatment of ROR1-positive hematological malignancies and solid tumors.